IlluminaXSWX:ILMN -0.79%76 Debt-to-EBITDA is 2.54 as of Mar. 2026, which is 63% above its 10-year median of 1.56. GuruFocus rates XSWX:ILMN with a GF Score™ of 76/100 and a GF Value™ of CHF105.33. The stock has 7 warning signs investors should review. Among 112 Medical Diagnostics & Research companies, Illumina ranks better than 57.14% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Illumina's Debt-to-EBITDA or its related term are showing as below:
XSWX:ILMN'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.72 Med: 1.56 Max: 2.12
Current: 1.78
During the past 13 years, the highest Debt-to-EBITDA Ratio of Illumina was 2.12. The lowest was -3.72. And the median was 1.56.
XSWX:ILMN's Debt-to-EBITDA is ranked better than 57.14% of 112
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.345
vs XSWX:ILMN: 1.78
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Illumina Debt-to-EBITDA Related Terms
Illumina Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Illumina's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:ILMN vs MTD, DGX, LH: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Illumina's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Illumina Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Illumina's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Illumina (XSWX:ILMN) has a Debt-to-EBITDA of 2.54 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Illumina. This is 63% above median its historical median of 1.56. According to the industry distribution chart, Illumina ranks #48 out of 112 companies in the Medical Diagnostics & Research industry, placing it in the top 42.9%.
Is Illumina's Debt-to-EBITDA too high?
Illumina's current Debt-to-EBITDA of 2.54 is 63% above median its 10-year median of 1.56. The Medical Diagnostics & Research industry median Debt-to-EBITDA is 2.35. Illumina's value of 2.54 is 8.3% above this industry median. Based on the distribution chart, Illumina ranks #48 out of 112 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Illumina has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Illumina's Debt-to-EBITDA compare to MTD and DGX?
According to the Medical Diagnostics & Research industry distribution chart, Illumina ranks #48 out of 112 companies for Debt-to-EBITDA. This puts Illumina in the upper half of its industry. The industry median Debt-to-EBITDA is 2.35. Illumina's value of 2.54 is 8.3% above this benchmark. While the company's 10-year median is 1.56 vs. the industry median of 2.35, Illumina has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.35, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Illumina's current Debt-to-EBITDA of 2.54 is 8.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Illumina. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Illumina's current Debt-to-EBITDA is 2.54, which is 63% above median its own 10-year median of 1.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Illumina stock overvalued right now?
Illumina (XSWX:ILMN) has a current Debt-to-EBITDA of 2.54. The stock's GF Value™ is CHF105.33, compared to a current price of CHF143.95 — trading 36.7% above its estimated fair value. The current Debt-to-EBITDA is 2.54, which is 63% above median its 10-year median of 1.56 and 8.3% above the Medical Diagnostics & Research industry median of 2.35. Illumina's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Illumina (XSWX:ILMN), the current Debt-to-EBITDA is 2.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Illumina (XSWX:ILMN) Overvalued in 2026?
Based on GuruFocus' analysis, Illumina stock appears to be overvalued.
The current stock price of CHF143.95 is trading 36.7% above its estimated GF Value™ of CHF105.33.
Key valuation signals for XSWX:ILMN:
Debt-to-EBITDA: 2.54 (63% above median its 10-year median of 1.56)
GF Value™: CHF105.33 vs. price of CHF143.95 (36.7% above fair value)
Industry Position: 8.3% above the Medical Diagnostics & Research median (#48 of 112)
No single metric tells the full story. See the XSWX:ILMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
76GF Score
Get the complete analysis for XSWX:ILMN
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ILMN has been successfully added to your 
